BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

IMCR upcoming catalysts

Immunocore Ltd: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 0 FDA event(s). Subscribe to IMCR (.ics).

Drugs: IMC-R117C, Kinase inhibitor, Antiangiogenic Agent, Monoclonal antibody, pembrolizumab, bevacizumab

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2Immunocore Ltd IMCRNCT06840119 Phase 1/2 Study of IMC-R117C in Selected Advanced CancersCancer; HLA-A*02:01-positiverecruiting600

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P1/P2Immunocore Ltd IMCRNCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsSelect Advanced Solid Tumorsactive not recruiting410

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.